← Eichor
Study identifier: NCT07220109 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study on the Immune Response and Safety of Vaccine Against Respiratory Syncytial Virus Given to Chinese Adults 18 to 59 Years of Age at Increased Risk of Respiratory Syncytial Virus Disease

Condition: Respiratory Syncytial Virus Infections  ·  Sponsor: GlaxoSmithKline

PhasePhase 3
Planned participants750
Who can joinAll sexes, 18 Years to 59 Years
Healthy volunteersNo

About this study

The study will evaluate the immune response of the RSVPreF3 OA investigational vaccine in Chinese adults 18 to 59 years of age (YOA) who are at increased risk of respiratory syncytial virus (RSV) disease, in comparison with the immune response generated in older adults 60 YOA and above from the 219815 (RSV OA=ADJ-021; NCT06551181) study following a single dose of the RSVPreF3 OA vaccine. In addition, the safety and reactogenicity of the vaccine will also be assessed.

This description comes directly from the study's public registry record.

Talk to the study team

US GSK Clinical Trials Call Center  ·  877-379-3718  ·  GSKClinicalSupportHD@gsk.com

EU GSK Clinical Trials Call Center  ·  +44 (0) 20 89904466  ·  GSKClinicalSupportHD@gsk.com

Always discuss trial participation with your own doctor first.

Locations (15)

GSK Investigational SiteBeijing, Beijing Municipality, ChinaRecruiting
GSK Investigational SiteXiangtan, Hunan, ChinaRecruiting
GSK Investigational SiteNanjing, Jiangsu, ChinaRecruiting
GSK Investigational SiteChengdu, Sichuan, ChinaRecruiting
GSK Investigational SiteChengdu, ChinaRecruiting
GSK Investigational SiteChongqing, ChinaRecruiting
GSK Investigational SiteChongqing, ChinaRecruiting
GSK Investigational SiteGuangzhou, ChinaRecruiting
GSK Investigational SiteGuangzhou, ChinaRecruiting
GSK Investigational SiteJiujiang, ChinaRecruiting
GSK Investigational SiteKunming, ChinaRecruiting
GSK Investigational SiteNanning, ChinaRecruiting

+ 3 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07220109